MBX Biosciences, Inc.
26 articles about MBX Biosciences, Inc.
-
MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors
2/5/2024
MBX Biosciences, Inc. today announced the appointment of Steven Ryder, M.D., Chief Medical Officer of Rallybio, to its Board of Directors.
-
MBX Biosciences to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
1/31/2024
MBX Biosciences, Inc. today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the virtual Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th , 2024, at 12:40 p.m. ET.
-
MBX Biosciences to Participate in 42nd Annual J.P. Morgan Healthcare Conference
12/20/2023
MBX Biosciences, Inc. today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th, 2024, at 11:30 a.m. PST and the Company will host one-on-one investor meetings during the conference.
-
MBX Biosciences to Participate in Piper Sandler 35th Annual Healthcare Conference
11/15/2023
MBX Biosciences, Inc. today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29th , 2023, at 9:10 a.m. Eastern Time and will host 1-on-1 investor meetings.
-
MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer
11/1/2023
MBX Biosciences, Inc. announced the appointment of Michelle Graham as Chief Human Resources Officer.
-
MBX Biosciences to Participate in Stifel 2023 Healthcare Conference
10/31/2023
MBX Biosciences, Inc. announced that Kent Hawryluk, President and Chief Executive Officer, will present at the Stifel 2023 Healthcare Conference on Tuesday, November 14th, 2023, at 2:25 p.m. Eastern Time and will host 1-on-1 investor meetings.
-
MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
10/3/2023
MBX Biosciences, Inc. today announced that results from the Phase 1 Study of MBX 2109, the company’s long-acting parathyroid hormone (PTH) peptide prodrug in development for the treatment of hypoparathyroidism (HP), will be featured in a late-breaking oral presentation at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting being held in Vancouver, Canada October 13-16, 2023.
-
MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults
9/11/2023
MBX Biosciences, Inc. today announced positive results from the multiple ascending dose (MAD) portion of the Phase 1 trial of MBX 2109.
-
MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference
8/29/2023
MBX Biosciences, Inc. announced that Kent Hawryluk, President and Chief Executive Officer, and Richard Bartram, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12th, 2023, at 11:30 a.m. Eastern Time and will host 1-on-1 investor meetings.
-
MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
8/7/2023
MBX Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for MBX 1416, the company’s long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist, being developed for the treatment of post-bariatric hypoglycemia (PBH).
-
MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer
7/10/2023
MBX Biosciences, Inc. today announced the appointment of Steven Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer (CSO).
-
MBX Biosciences to Participate in Jefferies 2023 Healthcare Conference
5/24/2023
MBX Biosciences, Inc. announced that Kent Hawryluk, President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 8th, 2023, at 2:30 p.m. Eastern Time and will host 1-on-1 investor meetings.
-
MBX Biosciences to Participate in May 2023 Investor Conferences
5/8/2023
MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ therapeutics to treat an array of endocrine disorders, announced management will participate in the following investor conferences.
-
MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference
4/10/2023
MBX Biosciences, Inc. today announced its participation at the virtual Needham 22nd Annual Healthcare Conference. Kent Hawryluk, President and Chief Executive Officer, will present on Monday, April 17, 2023 at 3:00 p.m. ET.
-
MBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
3/7/2023
MBX Biosciences, Inc. today announced its participation at the virtual Oppenheimer 33rd Annual Healthcare Conference. Kent Hawryluk, President and Chief Executive Officer, will present on Tuesday, March 14, 2023 at 10:40 a.m. ET.
-
MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
1/24/2023
MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced its participation at the virtual SVB Securities Global Biopharma Conference – Private Company Track.
-
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/5/2023
MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ therapeutics to treat an array of endocrine disorders, announced its participation at the 41st Annual J.P. Morgan Healthcare Conference.
-
MBX Biosciences secured $115 million in Series B financing to advance its pipeline of Precision Endocrine Peptides for endocrine disorders.
-
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
11/14/2022
MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ therapeutics to treat an array of endocrine disorders, announced the closing of a $115 million Series B financing.
-
MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109MBX 2109 is in clinical development for treatment of hypoparathyroidism
10/5/2022
MBX Biosciences, Inc. today announced that it has initiated the multiple ascending dose portion of its ongoing Phase 1 clinical trial of MBX 2109.